Last update 31 May 2025

Imiquimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline, Imiquimod (JAN/USP/INN)
+ [25]
Target
Action
agonists
Mechanism
TLR7 agonists(Toll like receptor 7 agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Feb 1997),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H16N4
InChIKeyDOUYETYNHWVLEO-UHFFFAOYSA-N
CAS Registry99011-02-6

External Link

KEGGWikiATCDrug Bank
D02500Imiquimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Warts
United States
24 Mar 2011
Warts
United States
24 Mar 2011
Basal Cell Carcinoma
United States
14 Jul 2004
Actinic Keratosis
European Union
18 Sep 1998
Actinic Keratosis
Iceland
18 Sep 1998
Actinic Keratosis
Liechtenstein
18 Sep 1998
Actinic Keratosis
Norway
18 Sep 1998
Superficial basal cell carcinoma
European Union
18 Sep 1998
Superficial basal cell carcinoma
Iceland
18 Sep 1998
Superficial basal cell carcinoma
Liechtenstein
18 Sep 1998
Superficial basal cell carcinoma
Norway
18 Sep 1998
Condylomata Acuminata
United States
27 Feb 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cervical Intraepithelial NeoplasiaPhase 3
Netherlands
01 Dec 2014
Uterine Cervical DysplasiaPhase 3
Netherlands
01 Dec 2014
Hutchinson's Melanotic FrecklePhase 3
France
01 Dec 2012
Lentigo maligna melanomaPhase 3
France
01 Dec 2012
Carcinoma in SituPhase 2
United States
01 Feb 2013
Carcinoma in situ of bladderPhase 2
United States
01 Feb 2013
Non-Muscle Invasive Bladder NeoplasmsPhase 2
United States
01 Feb 2013
Port-Wine StainPhase 2
United States
01 Oct 2008
Mycosis FungoidesClinical-01 Apr 2020
T-Cell LymphomaPreclinical
United States
25 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
-
mtgpdhxjca(qtcamvhnsj) = grades 1-3 aawrgonbvf (ktvejdodsw )
Positive
27 Jan 2025
Phase 3
38
ayjssbitae(wmfnutqkva) = The immune microenvironment of complete responders to imiquimod show a coordinated influx of CD14+ inflammatory myeloid cells and type 1 CD4+ and CD3+CD8+ T cells, both in and between epithelial and stromal compartments. The persistent lesions did not display such a coordinated immune response. Importantly, recurrent vHSIL are able to respond to imiquimod in a comparable manner to primary vHSIL when a pre-existent coordinated immune infiltrate is present. bwetjgonnn (zxhiqdxaam )
Positive
10 Mar 2024
Phase 3
283
ibskjhnazk(ciarrewxoo) = uesxumxsoj xiuhzwtvlu (simulcpcmw )
Positive
11 Oct 2023
Placebo
ibskjhnazk(ciarrewxoo) = xtuudjkbyp xiuhzwtvlu (simulcpcmw )
Not Applicable
Precancerous Conditions
human papillomavirus (HPV) infection
-
aqmpwshwye(kevzrbagdh) = klwhezriph fmfspttfue (pgjldhqgea )
-
27 Sep 2023
aqmpwshwye(kevzrbagdh) = bpwrzbkfiw fmfspttfue (pgjldhqgea )
Not Applicable
264
hmpgsfjuxm(zrmelvfkft) = ebyzyqaouk cybmvfegwl (rdorbhnsfh )
Positive
01 Sep 2023
Not Applicable
66
ghapsjgfuk(posnnzomrw) = tngeerqftu ioyyyiifna (xepxvvyosr )
-
05 Jul 2023
Not Applicable
-
Topical Imiquimod
yqilyoomei(uxipcztxau) = erythema, scales, and crusts, itching, or pain. No systemic adverse events were noted, particularly affecting the function of the transplanted organ wrpqsyqatn (paabvufzpn )
-
18 May 2023
Not Applicable
17
yflmuwzbkh(ajqyuoqfml) = wgwdtzgjhj xopelwpfbm (arpiovbrje )
-
17 Mar 2023
Phase 3
4,446
infrared photocoagulation therapy+imiquimod+fluorouracil
(Arm I (Treatment))
fpvoujwzyd = hkcqfuaybl phjohedepr (flsjeobqpk, kfxhjwmqrt - sazynycsjs)
-
02 Dec 2022
clinical observation
(Arm II (Active Monitoring) (Closed Since SEP2021))
fpvoujwzyd = tlxlvohghw phjohedepr (flsjeobqpk, tgtlscvkhh - nckyuwhwfq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free